Ofev Can Safely Treat Progressive Fibrosing ILDs in Japanese Patients

Ofev Can Safely Treat Progressive Fibrosing ILDs in Japanese Patients

306365

Ofev Can Safely Treat Progressive Fibrosing ILDs in Japanese Patients

With reasonable safety, Ofev (nintedanib) slowed lung function decline in Japanese patients with progressive fibrosing interstitial lung diseases (ILDs), according to a subgroup analysis of the Phase 3 INBUILD trial. Overall, this analysis provides further assurance to clinicians in Japan on Ofev’s benefits to patients there, with “no new or unexpected safety findings” from previous trial analyses evident, its researchers said. The study, “Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial…

You must be logged in to read/download the full post.